Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial
TLDR
- Quantum BioPharma's FDA clearance for Lucid-MS phase 2 trial positions it ahead in MS treatment, with Buy rating and $8 target.
- Lucid-MS inhibits PAD2 to block demyelination, a novel mechanism distinct from immune suppression, now entering double-blind placebo-controlled phase 2.
- This targeted therapy could halt MS progression with fewer side effects, offering hope for better quality of life.
- Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, reverses myelin damage in preclinical models, now advancing to human trials.
Impact - Why it Matters
This FDA clearance for Lucid-MS is a crucial step toward a potential new treatment for multiple sclerosis, a disease affecting millions worldwide. Unlike current therapies that suppress the immune system, Lucid-MS targets the root cause—demyelination—which could lead to more effective and safer options for patients. For investors, this milestone de-risks the drug candidate and could significantly boost Quantum BioPharma's valuation if the trial succeeds. Moreover, the collaboration with Harvard and Massachusetts General Hospital on imaging techniques may improve how MS progression is measured, benefiting the entire medical community.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of Lucid-MS, a first-in-class drug candidate for multiple sclerosis (MS). The trial will be randomized, double-blind, and placebo-controlled, marking a significant step forward for the company. Lucid-MS is designed to inhibit peptidyl arginine deiminase 2 (PAD2) and target demyelination—the underlying cause of MS—rather than broadly suppressing the immune system, offering a potentially more targeted approach. The editorial coverage also highlights Quantum BioPharma's parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School, focusing on a PET imaging tracer to quantify demyelination, which could enhance treatment monitoring.
The news comes as Quantum BioPharma prepares for its first clinical testing in MS patients, following successful Phase 1 trials in healthy volunteers that demonstrated favorable safety and tolerability. Analyst attention is growing, with Rodman & Renshaw initiating coverage with a Buy rating and an $8 price target. The editorial places Quantum BioPharma alongside major biopharmaceutical companies such as Sanofi, Roche Holding AG, Biogen, and Clene Inc., underscoring the competitive landscape in neurological disease research. For a comprehensive view of the press release, visit https://ibn.fm/cwPHa.
Quantum BioPharma is dedicated to developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Its lead compound, Lucid-MS, has shown in preclinical models the ability to prevent and reverse myelin degradation. The company also holds a stake in Unbuzzd Wellness Inc., which markets an OTC product called UNBUZZD, and Quantum retains rights to develop pharmaceutical versions. This FDA clearance is a pivotal milestone that could bring a novel therapy to MS patients who currently have limited options.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial
